PHARMACEUTICAL COMPOSITIONS AND METHODS FOR CONTROLLING CARDIOTOXICITY CAUSED BY CHEMOTHERAPY Russian patent published in 2021 - IPC A61K31/352 A61K31/136 A61K31/496 A61K31/704 A61P35/00 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: group of inventions relates to an anticancer pharmaceutical composition with reduced cardiotoxicity, comprising an anticancer agent and a protective agent, where the protective agent is selected from a group consisting of myricetin, robinetin, vitexin, tricetin, fisetin, 7,3',4',5'-tetrahydroxiflavone, myricitrin and their salt, and the anticancer agent is anthracycline or a salt thereof, a protein kinase inhibitor or a proteasome inhibitor, and wherein the molar ratio of the protective agent to the anti-cancer agent ranges from about 1:1 to about 1,000:1; as well as to methods of treating cancer and a method of preventing, reducing or eliminating cardiotoxicity caused by an anticancer agent, comprising administering said anticancer agents and protective agents; and to a kit containing said agents and instructions for use thereof.

EFFECT: group of inventions provides pharmaceutical compositions, kits and methods for reducing or eliminating cardiotoxicity caused by treating anthracycline cancer, a protein kinase inhibitor or a proteasome inhibitor.

71 cl, 29 dwg, 1 tbl, 30 ex